Anti glioma effect of doxorubicin loaded liposomes modified with Angiopep-2

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 3, 2011, Pages 409-414

  Danyu, Mei ^a,b   Huile, Gao ^a,b   Wei, Gong ^c   Zhiqing, Pang ^a,b   Xinguo, Jiang ^a,b   Jun, Chen ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Angiopep 2; Glioma; Liposome; Targeted drug delivery

Indexed keywords

ANGIOPEP 2; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROGOL 2000; PEPTIDE DERIVATIVE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; GLIOMA; GLIOMA CELL; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR CELL; TUMOR VOLUME; WEIGHT GAIN; ZETA POTENTIAL;

EID: 79957943676     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP11.068     Document Type: Article

References (20)

1. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007). Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb. Blood Flow Metab., 27: 909-918.
2. Bulnes S, Bilbao J, Lafuente JV (2009). Microvascular adaptive changes in experimental endogenous brain gliomas. Histol. Histopathol., 24: 693-706.
3. Chung NS, Wasan KM (2004). Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev., 56: 1315-1334.
4. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, Gabathuler R, Castaigne JP, Beliveau R (2008). Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem., 106: 1534-1544.
5. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Beliveau R (2008). Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther., 324: 1064-1072.
6. Genc DB, Canpolat C, Berrak SG (2011). Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Support. Care Cancer.
7. Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW (2011). Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision Repair. Cancer Res., 71: 2308-2317.
8. Gupta B, Torchilin VP (2007). Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother., 56: 1215-1223.
9. Ito S, Ohtsuki S, Terasaki T (2006). Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci. Res., 56: 246-252.
10. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007). Angiogenesis in brain tumours. Nat. Rev. Neurosci., p. 8.
11. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J, Jiang C (2009). Gene delivery targeted to the brain using an Angiopepconjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials, 30: 6976-6985.
12. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM (2000). Human glioblastoma cell lines: Levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res., 60: 2300-2303.
13. Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV, Wang CH (2009). Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials, 30: 3189-3196.
14. Pardridge WM (2007). Drug targeting to the brain. Pharm. Res., 24: 1733-1744.
15. Sanguino A, Lopez-Berestein G, Sood AK (2008). Strategies for in vivo siRNA delivery in cancer. Mini Rev. Med. Chem., 8: 248-255.
16. Shao K, Huang R, Li J, Han L, Ye L, Lou J, Jiang C (2010). Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J. Control Release, 147: 118-126.
17. Shen J, Zhan C, Xie C, Meng Q, Gu B, Li C, Zhang Y, Lu W (2010). Poly (ethylene glycol)-block-poly (d, l-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery. J. Drug Target.
18. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 106: 1489-1499.
19. van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM (2011). Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J. Control Release, 150: 30-36.
20. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W (2010). Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control Release, 143: 136-142.